Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2022
Industry sponsorship bias in cost effectiveness analysis: registry based analysis
22 June 2022 - The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and ...
Posted by Michael Wonder on 05 Nov 2020
Cost effectiveness of cancer drugs: comparative analysis of the United States and England
5 November 2020 - England's National Institute for Health and Care Excellence and the US’ Institute for Clinical and Economic Review ...
Posted by Michael Wonder on 05 Mar 2019
Future unrelated medical costs need to be considered in cost effectiveness analysis
5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...
Posted by Michael Wonder on 30 Oct 2018
Analysis of base-case ICERs accepted by the PBAC (July 2018)
30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual ...
Posted by Michael Wonder on 22 Mar 2018
What is the evidence from past NICE single-technology appraisals regarding company submissions with base-case incremental cost-effectiveness ratios of less than £10,000/QALY?
22 March 2018 - NICE has recently proposed that company submissions with a base-case incremental cost-effectiveness ratio of less than ...
Posted by Michael Wonder on 05 Jul 2016
Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal
3 July 2016 - This editorial considers the vexing issue of ‘unrelated future costs’ (for example, the costs of caring ...
Posted by Michael Wonder on 02 Nov 2015
Changes to number of copies of the economic model and category 1 requirements to be filed with CADTH
2 November 2015 - Going forward, CADTH has revised the number of copies of the economic model to be provided at ...